HCA

Business profile & competitive position

HCA Healthcare, Inc. sits in the Healthcare sector, specifically the Medical – Care Facilities industry. At December 31, 2025, it operated 190 hospitals split into 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals, plus 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers across 19 U.S. states and England. Its facilities deliver inpatient and outpatient medical/surgical care, emergency and diagnostic services, mental health services, and ancillary services through ASCs, urgent/walk-in clinics, physician practices, home health agencies, hospices, and rehabilitation facilities.

The scale is substantial: HCA’s general acute care hospitals alone held 50,436 licensed beds, while its behavioral hospitals held 714 licensed beds. In 2025 the company generated $75.6 billion in revenue, with 48.9% coming from managed care and other insurers and 14.9% from Medicare. That payer mix underlines a business model heavily tied to negotiated commercial rates and government reimbursements rather than a single dominant revenue stream.

On the profitability side, HCA’s 8.8% net margin shows it converts revenue into profit at a respectable level for capital-intensive hospital operations. However, its ROE is deeply negative at -112.9%. With net margin positive, that negative ROE implies negative book equity on the balance sheet — typically a sign of significant leverage or cumulative shareholder deficits — rather than operating losses. For competitive-position analysis, this means operational profitability looks steady, but the equity-return profile is not something that points to a wide moat measured by returns on shareholder capital.

Financial posture

HCA currently carries a market capitalization of $91.5 billion and trades at a P/E of 14.1. By broad-market standards, that valuation multiple is on the lower side, which is common for mature, capital-heavy healthcare services companies. The stock’s beta is 1.11, indicating it has historically moved slightly more than the overall market but not by a dramatic margin.

Net margin of 8.8% means HCA keeps roughly nine cents of profit on each dollar of revenue — reasonable for a hospital operator that faces significant labor, supply, and real-estate costs. The more unusual figure is the -112.9% ROE. Because ROE equals net income divided by shareholders’ equity, and net margin is positive, this extreme negative reading points to a leveraged balance sheet where shareholder equity could be negative or very small relative to net income. In practical terms, an analyst evaluating HCA needs to weigh attractive earnings generation and a mid-teens P/E against a balance-sheet structure that depresses, or inverts, the return-on-equity metric.

Strategic priorities & outlook

HCA’s most recent 10-K outlines four operational priorities. First, the company wants to grow its presence in existing markets rather than primarily expanding into brand-new geographies. Second, it aims to achieve industry-leading performance in clinical, operational, and satisfaction measures. Third, it emphasizes recruiting and retaining physicians and other healthcare professionals to meet demand for high-quality services. Fourth, it plans to advance its digital and artificial intelligence capabilities.

The filing also flags a notable concentration risk: HCA’s facilities and operations are heavily concentrated in Florida and Texas, making the company sensitive to local regulatory changes, economic conditions, public health trends, and competitive dynamics in those two states. With 2025 revenue of $75.6 billion largely flowing from those markets and from managed-care payers, execution on the stated priorities will have to happen in a regionally concentrated, commercially negotiated environment.

Macro & geopolitical exposure

As a medical care facilities operator, HCA’s macro exposure begins with healthcare policy and regulation. Hospital revenue depends on Medicare and Medicaid reimbursement rates, commercial insurance pricing, state-level certificate-of-need regimes, and federal legislation affecting the Affordable Care Act or surprise-billing rules. Any material change in reimbursement, especially from Medicare, which contributed 14.9% of 2025 revenue, directly affects profitability.

Labor is another macro factor. Physician and nurse availability, wage inflation, and staffing shortages influence both costs and the ability to admit and treat patients. HCA’s fourth strategic priority — recruiting and retaining healthcare professionals — reflects how tight labor markets can constrain growth.

Because hospitals are capital-intensive real-estate businesses, interest-rate levels matter for refinancing and capital expenditures. Higher rates increase the cost of funding new facilities, renovations, and equipment. Supply-chain and input-cost pressures also matter, including prices for pharmaceuticals, medical devices, and energy, some of which can be affected by trade policy. Currency exposure is limited because the bulk of operations are U.S.-based, though England introduces a small foreign-exchange element.

Recent developments

On September 10, 2026, Pomerantz Law Firm announced an investor alert investigating claims on behalf of HCA Healthcare investors, according to PR Newswire. That is a litigation/investor-relations development and not a concluded regulatory or court finding, but it is worth monitoring because securities investigations can affect sentiment regardless of outcome.

On September 9, 2026, HCA presented at the Wells Fargo 21st Annual Healthcare Conference, with the transcript published via Seeking Alpha. Management conferences often provide updates on volume trends, labor costs, commercial payer negotiations, and capital allocation, so the transcript is a primary source for how the company views its own operating environment.

Also on September 9, 2026, media coverage noted that Michael Burry, famous from “The Big Short,” had updated his portfolio for September, and a separate defenseworld.net article compared HCA Healthcare with OPKO Health. The Burry mention tends to draw retail and quant-driven attention, while the comparative analysis contributes to sector-relative discussion without necessarily carrying new company-specific fundamental information.

Earnings behavior & post-earnings drift

HCA has built a strong recent earnings track record. Over the last eight reported quarters, it beat expectations in all eight, a 100% beat rate, with an average earnings surprise of 6.4%. The average five-day price move in the trading sessions after earnings was +1.75%, classified as an upward drift.

Looking at the last four quarters, the pattern is more nuanced. On July 24, 2026, HCA reported EPS of $7.59 versus the $7.56 estimate, a 0.4% beat, and the stock rose 1.94% the next day and 5.34% over the following five days. On April 24, 2026, EPS came in at $7.15 versus $7.12, also a 0.4% beat, with the stock up 3.09% the next day but only 0.15% over the next five sessions.

The January 27, 2026 quarter showed a 7.4% surprise, with actual EPS of $8.01 versus the $7.46 estimate, yet the stock fell 2.89% the next day and 1.31% over the following five days — a classic “beat and sell” reaction. The prior quarter, October 24, 2025, featured a 20.2% surprise ($6.96 actual versus $5.79 estimate), and the stock rewarded it with a 4.66% next-day gain and a 2.83% five-day gain. The takeaway from this history is that HCA routinely clears the consensus bar, but the magnitude and direction of the stock response depend heavily on what the market’s real expectation was and on forward commentary.

HCA is scheduled to report next on October 23, 2026, before the open, with the current consensus EPS estimate at $6.71.

For a deeper dive into how institutional analysts are interpreting these figures, the recent conference commentary, and the latest legal developments, review the full institutional verdict rather than relying on headline numbers alone.